Kanchi Karpooram Limited (KANCHI) fundamentals

Kanchi Karpooram Limited is a listed company in Chemicals & Petrochemicals, part of the Chemicals sector, listed on the NSE as KANCHI (ISIN INE081G01019). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.

What Kanchi Karpooram Limited does

Kanchi Karpooram Limited is an India-based company, which is principally engaged in the business of the manufacture and sale of Camphor/allied products and in the trading of Agro products. The Company has a manufacturing plant at Kanchipuram in Tamil Nadu. Its product consists of Camphene, Camphor, Dipentene, Double Distilled Turpentine, Ester Gum, Fortified Rosin, Gum Rosin, Isoborneol, Isobornyl Acetate, Pine Oil, Pine Pitch, Pine Tar (Natural), and Sodium Acetate Trihydrate. The Company also serves a variety of other industries, namely tires, paint, paper, food, pharma, rubber, and a number of international traders who deal with a variety of industries. The Company's subsidiary is Kanchi Agro Product Private Limited.

Valuation and market data

Last close₹390.75
Market capitalisation₹164 crore
Enterprise value₹165 crore
P/E (TTM)0.00
Price to book0.78
Price to sales (TTM)1.03
Book value per share₹500.22
Dividend yield25.59%
SectorChemicals
IndustryChemicals & Petrochemicals
Listed sinceMon Apr 20

Annual results

PeriodRevenueProfit before taxNet profitEPS
Mar 2026₹153 crore₹7 crore₹5 crore0.00
Mar 2025₹155 crore₹18 crore₹13 crore31.59
Mar 2024₹148 crore₹1 crore₹-0 crore1.38
Mar 2023₹221 crore₹18 crore₹13 crore30.91

Figures are as reported (consolidated), in ₹ crore.

Shareholding pattern

As of Jun 2026:

Promoters51.2%
Foreign institutions (FII)0.0%
Mutual funds0.0%
Other domestic institutions0.0%
Retail and others48.8%

More on BreakPoint

FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.

Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.